Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Regan Andrew 2. Issuer Name and Ticker or Trading Symbol CONDUIT PHARMACEUTICALS INC. [CDT] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 4851 TAMIAMI TRAIL NORTH, SUITE 200 3. Date of Earliest Transaction (Month/Day/Year) 06/03/2025 (Street) NAPLES, FL 34103 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 06/03/2025 A 154,799 A $3.23(1) 154,799 I See Footnote(2) Common Stock 20,032(3) I See Footnote(4)(6) Common Stock 118(3) I See Footnote(5)(6) Common Stock 44(3) D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Regan Andrew 4851 TAMIAMI TRAIL NORTH, SUITE 200 NAPLES, FL 34103	X	X	Chief Executive Officer
Corvus Capital Ltd. 4851 TAMIAMI TRAIL NORTH, SUITE 200 NAPLES, FL 34103		X

Signatures

/s/ Andrew Regan		06/13/2025
**Signature of Reporting Person		Date
CORVUS CAPITAL LTD. By: /s/ Andrew Regan Name: Andrew Regan Title: Chief Executive Officer		06/13/2025
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Based on the closing price per share of the Issuer's common stock, par value $0.0001 ("Common Stock"), on June 3, 2025.
(2)	These shares of Common Stock are owned of record by Manoira Corporation ("Manoira"). On June 3, 2025, the Issuer issued 154,799 shares of Common Stock to Manoira pursuant to that certain joint development agreement (the "Joint Development Agreement") by and between the Issuer and Manoira, representing an up-front consideration of $500,000.
(3)	On January 24, 2025, the Issuer effected a 1-for-100 reverse stock split (the "January Reverse Split") and, on May 15, 2025, subsequently effected a 1-for-15 reverse stock split (together with the January 2025 Reverse Split, the "Reverse Splits"). The number of shares of Common Stock reported has been adjusted to give effect to the Reverse Splits.
(4)	These shares of Common Stock are owned of record by Corvus Capital Limited ("Corvus").
(5)	These shares of Common Stock are owned of record by Algo Holdings, Inc. ("Algo").
(6)	Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership except to the extent of its or his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.